The cost and benefit of targeting amyloid plaques to treat alzheimer’s disease

Marisa E Franklin and Glen A Franklin*

Alzheimer’s Ddisease (AD) is now the seventh leading cause of death in the United States. This incurable and fatal disease is becoming an increasingly concerning medical diagnosis. One feature of Alzheimer’s disease is a build-up of the peptide amyloid-beta in the brain that progressively interferes with the patient’s ability to retain memory and perform mental tasks. One of the newest strategies to combat AD is to target the excess amyloid-beta. Several new drugs have been in stages of clinical trials, with both Lecanemab and Aducanumab recently being deemed a scientific breakthrough by gaining Food and Drug Administration (FDA) approval. This review will address the various strategies scientists have taken to target amyloid-beta, discuss the cost versus benefit of the drugs, and attempt to place this information in context with this significant public health crisis.

Keywords:

Published on: Dec 30, 2023 Pages: 8-13

Full Text PDF Full Text HTML DOI: 10.17352/aadc.000027
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat